Last reviewed 2026-04-20 · How we verify

Chemotherapy Regimen 1 (chemotherapy-regimen-1)

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Anemia
• Neutrophil count decreased
• Creatinine increased
• Fatigue
• Peripheral sensory neuropathy
• Platelet count decreased
• Diabetic retinal oedema Study Eye
• Hypertension
• Nausea
• acute graft-versus-host disease
• Diabetic retinopathy Study Eye
• Urinary tract infection

Key clinical trials

• Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
• MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
• A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer (PHASE1)
• Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC (PHASE2)
• A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer (PHASE3)
• Volrustomig Priming Regimens Exploratory Phase II Platform Study (PHASE2)
• A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (PHASE3)
• Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Chemotherapy Regimen 1 CI brief — competitive landscape report
• Chemotherapy Regimen 1 updates RSS · CI watch RSS
• Pfizer Inc. portfolio CI